NCT03419689 is a NA clinical trial of Tumour tissue collection in Gynecologic Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT03419689?

NCT03419689 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT03419689?

Interventions in NCT03419689: Tumour tissue collection, Blood sample collection, Ascites Collection, Fluid Collection.

What condition does NCT03419689 study?

NCT03419689 studies Gynecologic Cancer.

Is NCT03419689 still recruiting?

NCT03419689 is currently recruiting now. Last updated 4 December 2025.

Last reviewed 2025-12-04 · How we verify

NCT03419689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Looking at Biomarkers in Ovarian Cancer

Recruiting now NA Last updated 4 December 2025

What this trial tests

NA trial testing Tumour tissue collection in Gynecologic Cancer in 510 participants. Currently enrolling.

Timeline

8 January 2018

Primary endpoint
8 June 2028

8 June 2028

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	510
Start date	8 January 2018
Primary completion	8 June 2028
Estimated completion	8 June 2028
Sites	7 locations across Canada

Drugs / interventions tested

Tumour tissue collection
Blood sample collection — full drug profile →
Ascites Collection
Fluid Collection

Conditions studied

Gynecologic Cancer — all drugs for Gynecologic Cancer →

Sponsor

University Health Network, Toronto

Who can join

18 and older, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
Colombo I, Karakasis K, Suku S, Oza AM. · · 2023 · cited 35× · PMID 37370830 · DOI 10.3390/cancers15123220
Double Trouble: Whole-Genome Doubling Distinguishes Early from Late Ovarian Cancer.
Yang SYC, Pugh TJ, Oza AM. · · 2022 · cited 3× · PMID 35476137 · DOI 10.1158/1078-0432.ccr-22-0336
Can <i>TP53</i> variant negative be high-grade serous ovarian carcinoma? A case series.
Kasherman L, Garg S, Tchrakian N, Clarke B, et al · · 2021 · cited 2× · PMID 33718561 · DOI 10.1016/j.gore.2021.100729

Verify or expand the search:

Other trials of Tumour tissue collection

Trials testing the same drug.

NCT03517917 — Prospective Tissue Collection Research Protocol · completed
NCT03420118 — Study of Biomarkers in Gynecological Cancers · NA · recruiting

Other recruiting trials for Gynecologic Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03419689 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 4 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03419689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing